Bigfoot is Now Abbott.

Together.

Expanding Impact.

Visit Abbott.com Newsroom

image-png-4

Abbott Completes Acquisition of Bigfoot Biomedical

ABBOTT PARK, Ill., September 22 — Abbott today announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

VIEW
BigfootUnity-1

Abbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes

ABBOTT PARK, Ill., and MILPITAS, CA, Sept. 5, 2023 –  Abbott and Bigfoot Biomedical today announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2023. Financial terms were not disclosed.

VIEW
Bigfoot_Logo_TM_Dark-2

Real-World Data Demonstrate the Potential for Rapid and Durable Improvement in Glycemic Control for People with Insulin-requiring Diabetes Using the Bigfoot Unity® System

Milpitas, Calif., June 21, 2023Bigfoot Biomedical (Bigfoot), a leader in developing simple and easy-to-use tools for people with insulin-requiring diabetes, today announced the publication of a six-month retrospective analysis of real-world use data of the Bigfoot Unity® System in the American Diabetes Association's (ADA) journal, Clinical Diabetes. In this initial 58-person cohort, results demonstrate the potential of the Bigfoot Unity System to support rapid and durable improvement in glucose control in people with diabetes who use multiple daily injections of insulin. 

VIEW
McGill press release, social image

Bigfoot Biomedical Acquires Reinforcement Learning Algorithm for Insulin Titration Developed at McGill University

Milpitas, Calif., March 30, 2023 - Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced the acquisition of a reinforcement learning algorithm for the titration of insulin settings developed at McGill University. The algorithm is designed to observe how well people with insulin-requiring diabetes respond to a particular insulin dose, and provide a recommended adjustment based on their body’s response.
VIEW
2023 Fast Company_Most Innovative Companies - Standard Logo

Bigfoot Biomedical Named to Fast Company’s “World’s Most Innovative Companies” List

Milpitas, Calif., March 9, 2023 – Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, has been selected as one of Fast Company's 2023 “World’s Most Innovative Companies” in the medical device category. Fast Company is the world’s leading business media brand, with an editorial focus on innovation in technology, leadership, world changing ideas, creativity, and design.

VIEW
BigfootUnity-1

Bigfoot Biomedical Receives FDA Clearance for Bigfoot Unity® Android App for People Living with Insulin-Requiring Diabetes

Milpitas, Calif., March 02, 2023 – Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced the U.S. Food and Drug Administration (FDA) has issued 510(k) clearance for the Android version of the Bigfoot Unity® Mobile App, a necessary component of the Bigfoot Unity® Diabetes Management System. Given that 41 percent of U.S. smartphone users choose Android devices1, this clearance enables expanded access to a large group of people with diabetes. Bigfoot Unity has been compatible with iOS devices since May 2021.
VIEW
home-office-336373_1920

Insulet Acquires Insulin Pump Patents from Bigfoot Biomedical as Both Companies Prioritize Improved Insulin Delivery Technologies

ACTON, Mass. & MILPITAS, Calif., Feb. 13, 2023 --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, and Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced Insulet has acquired assets related to Bigfoot’s pump-based automated insulin delivery (AID) technologies. Insulet paid $25M for the acquisition, which includes certain Bigfoot patents related to pumps that may be used for AID therapy. 

VIEW
towfiqu-barbhuiya-msQB97gUxY0-unsplash

Bigfoot Biomedical Announces Insulin Compatibility Expansion to Support Insulin Affordability and Flexibility for People with Diabetes

MILPITAS, Calif., November 07, 2022 Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, today announced its Bigfoot Unity® Diabetes Management System is now compatible with four additional rapid-acting insulin products, including two unbranded biologics. All four insulin products are offered at a reduced price without compromising quality, helping to expand insulin access for people with diabetes.

VIEW
Pens_Phone v0.2-libre

Bigfoot Unity® Demonstrates Strong Glycemic Control Among People with Type 2 Diabetes in Real-World Retrospective Analysis

Data Were Presented at the American Diabetes Association 82nd Scientific Sessions

MILPITAS, Calif., June 5, 2022 – Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, presented real-world data from its late-breaking abstract presented at the American Diabetes Association 82nd Annual Scientific Sessions. Data from the real-world retrospective analysis suggests that, for people on multiple daily injections (MDI) of insulin, using the Bigfoot Unity System has the potential for rapid and durable improvement in glycemic control.

VIEW
ADA 2022 Poster Presentation

Bigfoot Biomedical Announces Late-Breaking Poster Presentation and Product Theater at the 2022 American Diabetes Association 82nd Scientific Sessions

Milpitas, Calif., June 1, 2022 – Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, today announced late-breaking presentation of “The First Real World Experience with Bigfoot Unity: A 3-Month Retrospective Analysis” at the 2022 American Diabetes Association (ADA) 82nd Scientific Sessions.

VIEW
COO

Bigfoot Biomedical® Strengthens Leadership Team with Experienced Chief Commercial Officer

Milpitas, CA, May 26, 2022 - Bigfoot Biomedical, announced today Healthcare commercialization veteran Matt Rainville will lead commercial strategies. In this role, Rainville will lead the growth of the fully commercial Bigfoot Unity® Diabetes Management Program as Bigfoot expands access to diabetes clinics and health systems in 2022 and beyond.

 

VIEW
1636896516105-1

Bigfoot Biomedical® Adds Depth with Experienced, Senior New Hires

Milpitas, CA, December 16, 2021 - With its Bigfoot Unity™ Diabetes Management Program fully commercial, Bigfoot looks to broaden access to diabetes centers, endocrinology practices and health systems in 2022, as well as expand its development pipeline.

 
VIEW
Bigfoot Clinic Hub™ Puts Critical Data At Fingertips of Health Care Professionals

Bigfoot Clinic Hub™ Puts Critical Data At Fingertips of Health Care Professionals

Milpitas, CA, December 1, 2021 - Since launching in late summer 2021, the innovative Bigfoot UnityTM Diabetes Management Program and its Bigfoot Clinic HubTM are demonstrating that technology can help transform how health care professionals (HCPs) manage their patient populations on multiple daily injections (MDI) of insulin.

 
VIEW
Bigfoot Unity Program Now Available in US

Bigfoot Unity™ Program Now Available in US

Milpitas, CA, June 24, 2021 –Bigfoot Biomedical announced today that its innovative Bigfoot Unity™ Diabetes Management Program is now available to diabetes clinics and endocrinology practices in select markets across the U.S.

VIEW
common-sensing-gocap

Bigfoot Biomedical® Acquires Assets of Common Sensing

Milpitas, CA, June 15, 2021 –Bigfoot Biomedical announced today that it has acquired the intellectual property assets of Common Sensing, a Cambridge, MA-based company that develops and manufactures data-driven hardware and software solutions for people using injectable medicine, including Gocap.

VIEW
Bigfoot Unity Diabetes Management System

Bigfoot Biomedical® Receives FDA Clearance for Bigfoot Unity™ Diabetes Management System

Milpitas, CA, May 10, 2021 – Bigfoot Biomedical announced today that the FDA has granted 510(k) clearance for first-of-its-kind Bigfoot Unity™ Diabetes Management System, which features connected smart pen caps that recommend insulin doses for people using multiple daily injection (MDI) therapy.

VIEW
Madryn Asset Management Logo

$57M Financing from Madryn Asset Management

Milpitas, CA, March 17, 2021 – Bigfoot Biomedical announced today that it has secured new financing of up to $57 million from Madryn Asset Management LP

VIEW
Bigfoot-Commercial-Leaders

Bigfoot Biomedical® Builds Out Experienced Commercial Team

Milpitas, CA, December 9, 2020 – As it readies for FDA clearance of its first product and subsequent launch of its innovative program, Bigfoot Biomedical announced today it has established an experienced commercial team led by senior vice president Berkley Nelson.

VIEW
Jim Malone

Bigfoot Biomedical® Appoints Jim Malone MD Chief Medical Officer

Milpitas, CA, June 12, 2020 – Bigfoot Biomedical, Inc. announced today the appointment of Dr. Jim Malone as Chief Medical Officer. Dr. Malone, an endocrinologist specializing in diabetes, spent 12 years in clinical practice and 21 years in clinical research, where he developed diabetes products and delivery devices at Eli Lilly & Company.

VIEW
Bigfoot Series C Financing

Bigfoot Biomedical® Announces Close of its $55M Series C Round

Milpitas, CA, June 2, 2020- Bigfoot Biomedical® Closes Series C Financing with $55 Million as Company Readies for FDA Submission of Bigfoot Unity. Funding to Support its Breakthrough Therapy and Telemedicine Solutions for People Living with Insulin-Requiring Type 1 and Type 2 Diabetes

VIEW
COO and SVP roles announced

Bigfoot Biomedical® Announces New Roles and Reporting Structure

Milpitas, CA, March 13, 2020 – Bigfoot Biomedical, Inc. announced today key promotions and new reporting structures as the company readies for regulatory submission and commercial launch of Bigfoot Unity™ Diabetes Management Program. 

VIEW
Bigfoot Acquires Timesulin

Bigfoot Biomedical Acquires Timesulin - June 8, 2017

Milpitas, CA, United States, and London, England, June 8, 2017 – Bigfoot Biomedical, Inc., a new kind of medical device company harnessing the power of machine learning to automatically and continuously optimize insulin delivery for people with insulin-requiring diabetes, today announced that it has acquired London-based biotech company Patients Pending, LTD, makers of the Timesulin® insulin pen timer cap, and its Bluetooth-enabled insulin pen dose capture technology.

VIEW
Series C led by Abbott

Bigfoot Biomedical® Announces Initial $45 Million of a Series C Financing Led by Abbott

Milpitas, CA, January 13, 2020 –  Bigfoot Biomedical, Inc. announced today that the company has raised $45 million in the initial tranche of a Series C equity financing. The round is led by Abbott with support from existing investors, including Quadrant Capital Advisors, Senvest Capital, Janus Henderson, and Cormorant Asset Management.  
VIEW
AHN

Bigfoot Biomedical Announces Partnership with Allegheny Health Network to Advance Innovative Solution for People with Diabetes

Milpitas, CA, and Pittsburgh, PA – August 1, 2019 – Bigfoot Biomedical, Inc., and Allegheny Health Network (AHN) – a Highmark Health company – announced today a collaboration to further advance Bigfoot Biomedical’s first-in-kind data-driven solutions for optimizing the dosing and delivery of insulin for people with diabetes.

VIEW
Owen Mumford

Bigfoot Biomedical and Owen Mumford Announce Commercial Supply Agreement

Milpitas, CA, and Atlanta, GA. – February 7, 2019 – Bigfoot Biomedical, Inc., a diabetes company developing data-driven solutions for optimizing the dosing and delivery of insulin, today announced a commercial supply agreement with Owen Mumford, a global industry leader in medical device design and manufacturing, to support inclusion of Owen Mumford’s family of Unifine® Pen Needles into Bigfoot’s in-development connected injection system subscription supply bundles.
VIEW
Agreement with Lilly

Bigfoot Biomedical Announces Next Step for Connected Injection System

Milpitas, CA, Indianapolis, IN. – January 7, 2019 – Bigfoot Biomedical, Inc., a diabetes company using artificial intelligence to develop solutions for optimizing the dosing and delivery of insulin, today announced a non-exclusive cooperation agreement with Eli Lilly and Company (NYSE: LLY) to support integration of Lilly’s insulin products into Bigfoot’s systems currently in development.

VIEW
Google I/O 2018

Bigfoot Biomedical to be a Use Case in Session at Google I/O 2018 - May 10, 2018

Milpitas, California, May 10, 2018 – Bigfoot Biomedical, Inc., a diabetes solutions company using artificial intelligence to optimize the dosing and delivery of insulin for people with insulin-requiring diabetes, has been included as part of a demonstration showcasing new Android security features at the annual Google I/O developer conference in Mountain View, California.

VIEW
Series B Financing

Bigfoot Biomedical Announces Final Close of $55 Million Series B Financing - March 28, 2018

Milpitas, California, March 28, 2018 – Bigfoot Biomedical, Inc., a diabetes solutions company harnessing the power of artificial intelligence to optimize the dosing and delivery of insulin for people with insulin-requiring diabetes, today announced that the company has completed a $55 million Series B equity financing with new investments from Abbott and other new and existing investors, bringing the total amount of equity raised by the company to over $90 million.

VIEW
Initial Series B Financing

Bigfoot Biomedical Announces Initial $37 Million of a Series B Financing Led by Funds Managed by Janus Henderson and Entities Advised by Quadrant Capital Advisors - December 18, 2017

Milpitas, California, December 18, 2017 – Bigfoot Biomedical, Inc. today announced that the company has raised $37 million in the initial tranche of a Series B equity financing. The round is co-led by funds managed by a new investor, Janus Henderson Investors, along with Bigfoot’s largest existing investor, Quadrant Capital Advisors, Inc.

VIEW
Diabetes Technology Meeting

Bigfoot Biomedical Presents Data from Clinical Research Center Trial and Simulation Modeling at Diabetes Technology Meeting - November 3, 2017

Milpitas, California, November 3, 2017 – Bigfoot Biomedical, Inc., a medical device company harnessing the power of artificial intelligence to automatically and continuously optimize insulin delivery for people with insulin-requiring diabetes, will present data from a clinical trial at the 17th Annual Diabetes Technology Meeting in Bethesda, Maryland.

VIEW
Ypsomed Announce

Bigfoot Biomedical And Ypsomed Announce Agreement - October 24, 2017

Milpitas, California, United States, and Burgdorf, Switzerland, October 24, 2017 – Bigfoot Biomedical and Ypsomed (SWX:YPSN) today announced that the companies have entered into an agreement under which Ypsomed will supply Bigfoot with a customized proprietary version of its Orbit® infusion sets as part of Bigfoot’s investigational automated insulin pump-based solution for use in a pivotal trial.

VIEW
Abbott

Abbott and Bigfoot Biomedical Announce Collaboration to Develop Breakthrough Diabetes Technologies - July 13, 2017

Abbott Park, Ill., and Milpitas, Calif., July 13, 2017 – Abbott and Bigfoot Biomedical today announced that the companies have entered into an agreement to develop and commercialize diabetes management systems, integrating Abbott's FreeStyle® Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States.

VIEW
Board of Directors: Karen Talmadge

Bigfoot Biomedical Welcomes Karen Talmadge to Board of Directors - May 24, 2017

Milpitas, CA, May 24, 2017 – Bigfoot Biomedical, Inc., a new kind of medical device company harnessing the power of machine learning to automatically and continuously optimize insulin delivery for people with insulin-requiring diabetes, today announced that biomedical industry entrepreneur Karen Talmadge, PhD, has joined its experienced Board of Directors.

VIEW
Clinical Board

Bigfoot Biomedical Announces Clinical Advisory Board - May 18, 2017

Milpitas, CA, May 18, 2017 – Bigfoot Biomedical, Inc., a privately held innovative machine learning company focused on developing solutions intended for people with insulin-requiring diabetes, today announced the members of its Clinical Advisory Board which will provide expert guidance to the team at Bigfoot working to develop an innovative product portfolio.

VIEW
T1D Exchange

Bigfoot Biomedical Receives Investment from T1D Exchange - February 15, 2017

Milpitas, CA, February 17, 2017 – Bigfoot Biomedical, Inc. today announced a significant investment from T1D Exchange, a nonprofit organization driving faster, more informed research and commercialization efforts to improve outcomes for people with T1D. The collaboration with Bigfoot marks the first investment out of T1D Exchange’s multi-million dollar initiative to accelerate the development and delivery of automated insulin delivery technology and solutions.

VIEW
JDRF T1D Fund

Bigfoot Biomedical Receives Investment from JDRF T1D Fund - January 26, 2017

Milpitas, CA, January 27, 2017 – Bigfoot Biomedical, Inc., a highly anticipated machine learning company founded by people directly impacted by Type 1 Diabetes (T1D), today announced an equity investment from the newly established JDRF T1D Fund, a strategic venture philanthropy fund with a focus on making high‐impact, early‐stage investments to accelerate commercial development of life‐changing therapies for people living with T1D.

VIEW
Series A Funding

Bigfoot Biomedical Raises $35.5 Million in Series A Financing - October 19, 2016

Milpitas, CA, October 19, 2016 – Bigfoot Biomedical, Inc., a highly anticipated precision medicine company founded by people directly impacted by Type 1 Diabetes (T1D) today announced a Series A investment of $35.5 million, led by entities advised by Quadrant Capital Advisors, with participation from Cormorant Asset Management, Senvest Capital, and Visionnaire Ventures. The funding will support final development activities for Bigfoot’s smartloop™ automated insulin delivery service, the world’s first Internet-of-Things medical device system delivered as a monthly service.

VIEW
First Clinical Trial

Bigfoot Biomedical Enrolls First Patients in Clinical Trial of smartloop™ Automated Insulin Delivery System - July 21, 2016

Milpitas, CA, July 21, 2016 – Bigfoot Biomedical, Inc., a company founded and led by people affected by and living with Type 1 Diabetes (T1D), has enrolled its first patients in a clinical trial for the Bigfoot smartloop™ automated insulin delivery system.

VIEW
Dexcom

Bigfoot and Dexcom Sign Partnership Agreement - June 3, 2015

New York, NY — Bigfoot Biomedical, Inc. today announced it has entered into a development agreement with Dexcom, Inc. to integrate data from the Dexcom Continuous Glucose Monitoring (CGM) System into the Bigfoot insulin delivery system. Bigfoot Biomedical is developing a comprehensive Type 1 Diabetes (T1D) Management System employing simple design, cloud connectivity, and human-centered-automation. The newly announced partnership will enable glucose data to travel seamlessly from the Dexcom transmitter into the Bigfoot system to enable automated delivery of insulin for people with T1D.

VIEW
Asante

Bigfoot Biomedical Acquires the Assets of Asante Solutions - May 28, 2015

New York, NY, May 28, 2015 – Bigfoot Biomedical, Inc., a company developing a comprehensive Type 1 Diabetes (T1D) Management System employing simple design, cloud connectivity, and human-centered-automation, today announced it has acquired all assets of Asante Solutions, manufacturer of the Asante Snap insulin pump. The acquisition marks a strategically meaningful step towards Bigfoot’s broader vision to provide all people with T1D an accessible, affordable, automated, connected solution.

VIEW